Targeted Sensitization of Leukemic T-cells to Anticancer Drugs by SIRT1 Agonist SRT-1720
SRT-1720 induces oxidative stress and apoptosis in leukemic lymphocytes through SIRT1-independent pathway(s). In contrast, it enhances antioxidant defense in normal lymphocytes through a SIRT1-dependent pathway. These findings highlight the potential of SRT-1720 as an adjuvant to chemotherapy in T-ALL, particularly in drug combinations demonstrating strong synergism, which may allow dose reduction and decreased toxicity.
Authors
- Biliana Nikolova
- Plamen Getsov
- Rumiana Bakalova
- Donika Ivanova
- Zhivko Zhelev (ORCID: https://orcid.org/0000-0002-0106-2401)
- Dessislava Lazarova
- Vasil Hadjidekov
Institutions
- Trakia University (BG)
- Bulgarian Academy of Sciences (BG)
- Medical University of Sofia (BG)
- Institute of Biophysics and Biomedical Engineering (BG)
- Sofia University "St. Kliment Ohridski" (BG)
Publication Details
- Journal
- Anticancer Research
- Published
- 2026-01-30
- DOI
- https://doi.org/10.21873/anticanres.17981
- Primary Topic
- Sirtuins and Resveratrol in Medicine
- Type
- article
- Field-Weighted Citation Impact
- 0.00